A study assessing efficacy of 8 or 12 week ledipasvir/sofosbuvir (LDV/SOF) in treatment-naïve patients with non-cirrhotic, genotype 1 Hepatitis C: A study from TRIO Network.
Latest Information Update: 14 Mar 2016
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Gilead Sciences
Most Recent Events
- 14 Mar 2016 New trial record